Severe adverse reactions are rare with infusions of infliximab in a community setting
- New York University School of Medicine, NYU Hospital for Joint Diseases, New York, USA
- Correspondence to Yusuf Yazici
246 East 20th Street, New York, NY 10003, USA; yusuf.yazici{at}nyumc.org
In this study, Ducharme and colleagues report on the experience in community infusion centres with patients using infliximab for a variety of indications. As the authors state, randomised clinical trials are not the ideal environment to assess safety,1 2 and ‘real-world’ experience after the drugs are available to use give us a more complete picture for both the efficacy and the safety of any medication. This is a commendable effort that will provide important information for practitioners and patients alike.
In this retrospective chart review study, all infusions …
